Clinical Trial Update: Cardiotoxicities in Patients Receiving BTKi

View source ↗

Summary

A clinical trial evaluating cardiotoxicities in patients receiving Bruton's tyrosine kinase inhibitors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BTK inhibitors (Bruton tyrosine kinase inhibitor)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Status: WITHDRAWN